Ipratropiumbromid Teva

Ipratropium bromide, the active ingredient in Ipratropiumbromid Teva, is an anticholinergic (muscarinic antagonist) presented as an inhalation formulation for inhalation use. It provides bronchodilation to manage chronic obstructive pulmonary disease (COPD) and asthma in adult patients. By blocking muscarinic receptors in airway smooth muscle, it produces sustained airway opening and reduces mucus secretion.

GNH USA supplies Ipratropiumbromid Teva as a licensed, GDP‑compliant international pharmaceutical supplier, providing reliable quality and regulatory compliance to hospitals, pharmacies and clinics worldwide, ensuring timely delivery and adherence to local import regulations.

Ipratropium bromide is an anticholinergic bronchodilator that acts on the respiratory tract to improve airflow in obstructive airway diseases. - Chronic obstructive pulmonary disease (COPD): improves lung function, reduces dyspnea and exacerbations. - Asthma: provides maintenance bronchodilation and helps control symptoms. - Bronchospasm: delivers rapid airway relaxation to alleviate acute bronchoconstriction. - Exercise‑induced bronchoconstriction: reduces airway narrowing during physical activity.

Ipratropium bromide may cause a range of adverse reactions, most of which are related to its anticholinergic activity in the respiratory tract.

Common Side Effects: - Dry mouth. - Cough or throat irritation. - Headache. - Dizziness. - Nausea. - Taste alteration.

Serious or Rare Side Effects: - Severe allergic reaction (anaphylaxis). - Paradoxical bronchospasm. - Urinary retention. - Exacerbation of narrow‑angle glaucoma. - Angioedema. - Tachycardia.

When prescribing ipratropium bromide, clinicians should consider several precautionary measures to ensure safe use. - Assess renal function: dose adjustment may be needed in severe renal impairment. - Monitor for anticholinergic effects: watch for dry mouth, constipation, urinary retention. - Caution in patients with narrow‑angle glaucoma: may exacerbate intraocular pressure. - Avoid use in patients with known hypersensitivity to ipratropium or formulation excipients. - Store at room temperature: keep in original container, protect from moisture and light.

Ipratropium bromide can interact with other medications, altering its efficacy or increasing adverse effects.

Major Interactions (Avoid): - Concurrent use with other anticholinergic agents: increased anticholinergic burden. - Oral antihistamines with anticholinergic properties: additive dryness and urinary retention.

Moderate Interactions (Monitor Closely): - β2‑agonists: additive bronchodilation may increase risk of tachycardia. - Theophylline: may enhance bronchodilator effect. - Inhaled corticosteroids: monitor for combined respiratory effects.